Tetraphase launches Xerava in the U.S.

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) launched Xerava eravacycline in the U.S. to treat complicated intra-abdominal infections (cIAIs) in adults at a wholesale acquisition cost (WAC) of $175 per day. According to its U.S. label, Xerava is to be given for 4-14 days, for a total cost of $700-$2,450 per treatment cycle...